Vertex announces UK approval for CASGEVY™
Congratulations to Vertex for their UK approval for CASGEVY™, a CRISPR/Cas9 gene-edited therapy, for...
read DetailsAlthough Modality Solutions LLC is not mentioned in this New York Times, August 12, 2019 article on a possible cure for Ebola, we were asked to assist with this study because of our reputation of expertise in the field and previous collaboration with BARDA, CDC, and NIH during the 2015 – 2016 Ebola outbreak in West Africa. The Mitchell Group (TMG) and Leidos Biomed, working with the US National Institute of Health (NIH) and World Health Organization (WHO) requested our assistance for storage and transport of time and temperature-sensitive products (TTSPs) such as the investigational drugs, biological specimens, and laboratory reagents. In February and March 2019, our Subject Matter Experts (SMEs) traveled to the eastern provinces of the Democratic Republic of Congo (DRC) to evaluate and address cold chain management deficiencies. During their time in country, they provided cold chain training to local staff, conducted site assessments, and qualified critical equipment for the study.
Congratulations to Vertex for their UK approval for CASGEVY™, a CRISPR/Cas9 gene-edited therapy, for...
read DetailsCongratulations to Melinta Therapeutics for their FDA Approval of REZZAYO™ for the Treatment of...
read DetailsCongratulations to Iveric Bio for their FDA approval for IZERVAY™️️, a new treatment for...
read Details